Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 32

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Systemic lupus erythematosus

Recruiting

Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Caba-201
  • Sponsor:Cabaletta Bio Inc.

Colitis ulcerative+1

Recruiting

Study of adalimumab and infliximab dose adjustment guided by fecal calprotectin monitoring in adolescents and young adults with Crohn's disease or ulcerative colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Adalimumab
  • Sponsor:Universitair Medisch Centrum Groningen

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Rheumatoid arthritis

Recruiting

Study on Adjusting Adalimumab Dosage for Patients with Rheumatoid Arthritis in Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

HIV infection

Recruiting

Study of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Crohn's disease

Recruiting

Study on the Safety and Effectiveness of Mesenchymal Stem Cells for Treating Intestinal Strictures in Crohn's Disease Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Centre hospitalier universitaire de Liege

Psoriatic arthropathy+1

Recruiting

Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Justus-Liebig-Universitaet Giessen

Combined immunodeficiency

Recruiting

Study on Gene Therapy for Severe Combined Immunodeficiency (SCID) Using ARTEGENE in Patients with Artemis Gene Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Containing The Human Dclre1C Gene
  • Sponsor:Assistance Publique Hopitaux De Paris

Rheumatoid arthritis+1

Recruiting

Study on Morning vs. Evening Dosing of Tofacitinib for Patients with Rheumatoid or Psoriatic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tofacitinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Immunosuppression

Recruiting

Study on the Effect of Recombinant Human Interferon Gamma 1b for Patients with Post-Aggressive Immunosuppression in Intensive Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic sclerosis pulmonary

Recruiting

Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Chronic graft versus host disease

Recruiting

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.